Editas: The Most Comprehensive CRISPR Platform - But At What Cost? [Seeking Alpha]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Seeking Alpha
Summary Editas Medicines ( EDIT ) has the most mature and comprehensive editing preclinical platform of the CRISPR big three: CRISPR Therapeutics ( CRSP ), Editas and Intellia Therapeutics ( NTLA ). An integrated genomic medicine platform represents the “product portion” of any investigational drug application “IND” in contrast to the Chemistry, Manufacturing and Controls “CMC” component which drives more of the regulatory pathway duration at the FDA. This platform position is valuable both for collaborated and owned indications. Unfortunately, the cost of this licensed technology is too steep and in my view shareholder-unfriendly. This article is part of a series on genomic medicine which is poised to transform healthcare over the next two decades. My first article entitled Genomic Medicine: Catch the Gene Therapy Wave is a primer providing context for this article Why are editing platforms important? I’ll let FDA Commissioner Scott Gottlieb answer
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth [Reuters]Reuters
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth [Yahoo! Finance]Yahoo! Finance
- Crispr Therapeutics: Now Is The Time To Buy [Seeking Alpha]Seeking Alpha
- Aspen Ideas: Health Announces Global Health Experts to Speak at Annual Summit [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/21/24 - Beat
CRSP
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form 144
- 4/10/24 - Form SC
- CRSP's page on the SEC website